Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis

Suma Babu1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, Correspondence[email protected]
View further author information

Eric A. Macklin2 Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, View further author information

Katherine E. Jackson3 Office of the Prescription Drug Monitoring Program, Maryland Department of Health, Baltimore, MD, USA, View further author information

Elizabeth Simpson4 McCance Center for Brain Health at Massachusetts General Hospital, Boston, MA, USA, View further author information

Katy Mahoney1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, View further author information

Hong Yu1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, View further author information

Jason Walker1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, View further author information

Zachary Simmons5 Penn State Health Hershey Medical Center, Hershey, PA, USA, View further author information

William S. David1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, View further author information

Paul E. Barkhaus6 Medical College of Wisconsin, Milwaukee, WI, USA, View further author information

Laura Simionescu7 SUNY Upstate Medical Center, Syracuse, NY, USA, View further author information

Mazen M. Dimachkie8 University of Kansas Medical Center, Kansas City, KS, USA, View further author information

Alan Pestronk9 Washington University School of Medicine, St. Louis, MO, USA, View further author information

Johnny S. Salameh10 American University of Beirut Medical Center, Beirut, Lebanon, View further author information

Michael D. Weiss11 University of Washington Medical Center, Seattle, WA, USA, View further author information

Benjamin Rix Brooks12 Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte, NC, USA, andView further author information

David Schoenfeld2 Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, View further author information

Jeremy Shefner13 Barrow Neurological Institute and University of Arizona College of Medicine, Phoenix, AZ, USAView further author information

Swati Aggarwal1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, View further author information

Merit E. Cudkowicz1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, View further author information

Nazem Atassi1 Department of Neurology, Sean M Healey & AMG Center for ALS at Massachusetts General Hospital, Neurological Clinical Research Institute, Boston, MA, USA, View further author information

show all

Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date